Category: Uncategorized

Laboratorios Farmacéuticos ROVI, S.A. (ROVI or the “Company”), Càrniques Celrà, S.L. and Grupo Empresarial Costa, S.L. present Glicopepton Biotech, S. L., a joint venture that involves the creation of one of the first national structures for self-sufficiency in heparins and products of high nutritional value to be used in the composition of animal feed and fertilisers. The goals of this project focus on transforming the present livestock production process into a high-value-added technological process based on a circular economy model.

The project involves the construction of a facility at the Industrial Logistics Platform of Fraga (Huesca), which will produce compounds of high biological value that derive from the intestinal mucosa of pigs. It will involve a joint investment of approximately 40 million euros over the next four years and is expected to create around 30 direct skilled jobs. The project will be subject to obtaining the applicable administrative and regulatory permits and authorisations.

Glicopepton Biotech combines ROVI’s experience as a leading company in the research into low-molecular-weight heparins (LMWH) with the track records of Càrniques Celrà and Grupo Empresarial Costa, two major companies in the livestock and meat industry in Spain. LMWHs are anticoagulant drugs used to prevent and treat venous thromboembolic disease. They are a biological product whose raw material is obtained from the intestinal mucosa of pigs. This project seeks both the creation of economic and technological value, transforming pig mucosa into a high-value-added product like heparin, and the development of new animal food supplements and fertilisers.

ROVI has in-house production capacity to transform raw heparin into sodium heparin and intends to expand this capacity through the construction of a new sodium heparin production line (already underway), in order to be present in all the manufacturing phases of low-molecular-weight heparins.

Juan López-Belmonte Encina, ROVI’s chairman and chief executive officer, highlighted “the strategic importance for Spain of a project with these characteristics, since it provides the country with the capacity to be self-sufficient in obtaining a raw material that is indispensable for the production of an essential medicine like low-molecular-weight heparins. At ROVI, we are very excited about this project since, as a company specialised in these medicines, it will enable us to take a further step in the vertical integration of our LMWH manufacturing.”

The Andalusian Minister of Health and Consumer Affairs, Catalina García, participated this Monday in the informative breakfast organised by the newspaper Ideal de Granada and sponsored by Laboratorios Farmacéuticos ROVI.

During the event, the Andalusian head reviewed the challenges facing the region in the coming years, which include improving the conditions of the research community in the region and attracting companies linked to R&D&I in health as a source of wealth generation and qualified employment.

García assured that a “firm commitment to R&D&I in Health has been one of the strategic lines of the Andalusian Government since 2019, which is perceived as an essential factor in the search for solutions to the citizens’ health problems”.

The Regional Minister also dedicated a few words to highlight the role of ROVI in Andalusia, especially for the role it played during the pandemic in the manufacture of the Moderna vaccine: “It is one of the great business strongholds of the province of Granada and Andalusia”, she emphasised.

Do you want to know how to avoid phishing? Then don’t miss the following video. Click on the image to watch it

After two years of stoppage due to the pandemic, ROVI’s employees have been able to resume their activity of face-to-face corporate volunteering to participate in the last edition of the Descent of the River of the River Sella Adapted, held last July 31 and organized by the Federation of Sports for People with Physical Disabilities of the Principality of Asturias (FEDEMA).

It is one of the forms of social work that our professionals like the most and consists of accompanying the athletes of the Foundation also during the tour in double canoe.

160 athletes participated in this event, 64 of whom were athletes with disabilities. They started the descent in the facilities of the Asturian School of Canoeing in Arriondas to complete the first non-competitive stretch of 10 kilometers until the revolt known as The Nail. There they made a stop before starting the competitive five-kilometer stretch, whose goal was located on the Feve bridge in Llovio (Ribadesella).

“It was an experience of great personal satisfaction and we would certainly repeat it,” said Raquel Martínez and Belén Paniagua, process engineering technicians at the Alcalá de Henares plant. “We were delighted that ROVI gave us the opportunity to support such a beautiful and necessary cause, and he could be a useful and supportive figure for the members of the Foundation TAMBIÉN. This edition has been very special for us, not only for the incredible experience lived with our colleagues, but for bringing us friends for life. “

The sporting event concluded with the award ceremony and a twinning meal for all participants at the Arriondas Municipal Sports Centre, in which the organizers thanked all the collaborators for their help, including the assistance services, which allowed the edition to be held without incident.

About his volunteer experience,Loreto Monleón, Quality Assurance technician at the San Sebastián de los Reyes plant, highlighted:“I think he has contributed a lot to both parties. I take home the affection, gratitude and friendship of the people we have helped to carry out an activity that would otherwise have been more difficult for them to carry out. They have taught me to see life in a much more optimistic way, and that the barriers are not to stop us, but to bring them down. “

Through its volunteer programme, ROVI continues to bet on promoting the inclusion of people with disabilities in the competitive sport arena, while providing unique life experiences to all those involved through its activities.

• Laboratorios Farmacéuticos ROVI, SA, (“ROVI”) has obtained the best ESG score from among the 458 companies evaluated in its pharmaceutical subindustry category.
• With an ESG risk rating of 17.3 points, ROVI remains in a low-risk position and shows an improvement of 1.1 points on the previous year’s rating (18.4 points).

In July 2022, the Environmental, Social and Governance (ESG) aspects of ROVI were evaluated by Sustainalytics, a leading independent ESG and corporate governance research, ratings and analytics firm that supports investors around the world with the development and implementation of responsible investment strategies. ROVI obtained the best rating from among the 458 companies evaluated in the pharmaceutical subindustry. This year, ROVI has obtained an ESG risk rating of 17.3 points, thus continuing in a low-risk position (between 10 and 20 points).

This rating shows an improvement of 1.1 points on last year’s rating (18.4 points) and places ROVI at the top of the ranking in its pharmaceutical subindustry worldwide. Among the 970 companies in the industry, which includes biotechnology companies, pharmaceutical laboratories and medical device companies, ROVI is in 22nd place.

Among the actions that have allowed ROVI to improve its rating in 2022, its commitment to the environment may be highlighted, due to the implementation of greenhouse gas reduction programmes and the use of renewable energy. Additionally, ROVI has been considered the sector leader in aspects such as the

oversight of material ESG issues by senior management and its anti-corruption / anti-bribery policy in the Corporate Governance chapter, together with, in the Social area, the implementation of a sound equality and non-discrimination policy.

ROVI’s rating may be consulted on the following link: https://www.rovi.es/sites/default/files/Laboratorios_Farmace%C3%BAticos_Rovi_SA_RiskRatingsSummaryReport_07_28_2022.pdf

• Operating revenue increased by 31% to 380.4 million euros driven by (i) the strength of the contract manufacturing organization (“CMO”) business, which grew by 76%, and (ii) the specialty pharmaceutical business, where sales rose 9%. 
• Sales of the heparin franchise (Low Molecular Weight Heparins (LMWH) and other heparins) increased by 8% to 141.6 million euros. Sales of the enoxaparin biosimilar increased 31% to 82.1 million euros and sales of Bemiparin decreased 14% to 55.8 million euros.
• EBITDA increased by 56% to 115.8 million euros.
• Net profit increased by 58% to 80.6 million euros.
• ROVI General Shareholders Meeting, on 14 June 2022, approved the payment of a gross dividend of 0.9556 euros per share on 2021 earnings; it means an increase of 151% compared to the dividend on 2020 earnings (€0.3812/share) and represents a 35% pay out. This dividend was paid on 7 July 2022.

END OF THE SHARE BUY-BACK PROGRAMMES AND CAPITAL REDUCTION THROUGH CANCELLATION OF SHARES

ROVI reported that, at its meeting of 22 February, 2022, the Board of Directors decided to end the first share buy-back programme, launched by the Company as of 3 November, 2021, having acquired a total of 1,492,108 ROVI shares, i.e. 89% of the maximum number of shares it had been initially planned to acquire under the buy-back programme.

Likewise, on 29 March, 2022, ROVI reported the end of the second buy-back programme, which had commenced on 23 February, 2022. A total of 560,700 treasury shares had been acquired, i.e. 100% of the maximum number it had been initially planned to acquire under the buy-back programme.

The purpose of the two buy-back programmes was to cancel treasury shares held by ROVI (by reducing the capital). The reduction of the capital through cancellation of 2,052,808 shares repurchased within the framework of the aforementioned buy-back programmes was approved at the General Shareholders’ Meeting of 14 June, 2022 and executed by entering the pertinent deed of capital reduction into public record. The deed is currently undergoing the registration process at the Madrid Companies Registry and the new amount of the share capital, after the shares mentioned have been cancelled and excluded from trading will appear in the registers of the National Securities Market Commission and Iberclear a few days after registration of the deed of capital reduction. The Company will provide further information in due course.

OUTLOOK

For 2022, ROVI expects its operating revenue to increase between 15% and 20%.

Don’t miss this 360º adventure through the office. Click on the image to start.